Janux Therapeutics, Inc. (NASDAQ:JANX), a clinical-stage biotechnology company developing T-cell-engager cancer therapies, is advancing its lead prostate-cancer candidate and a broadening pipeline, backed by a very large cash position.
Gentex Corporation (NASDAQ:GNTX), a maker of automatic-dimming mirrors and electronic products for the auto industry, beat earnings expectations in the second quarter on favorable product mix and cost control, even as its revenue came in below forecasts.
Crane NXT, Co. (NYSE:CXT), a provider of payment, currency and authentication technologies, topped expectations in the second quarter with organic growth driving margin expansion and a record backlog, and it raised its outlook.
ExlService Holdings, Inc. (NASDAQ:EXLS), a data-analytics and digital-operations company, beat expectations in the second quarter with strong revenue growth led by a surge in its AI-related business, and it raised its full-year guidance.
GDEV Inc. (NASDAQ:GDEV), a mobile-gaming company behind titles such as Hero Wars, grew its net profit and generated positiveOperating Cash Flowin the second quarter, even as its revenue and bookings declined on lower paying-user counts.
Genpact Limited (NYSE:G), a provider of digital operations, data and artificial-intelligence services, beat expectations in the second quarter as its advanced-technology services accelerated, and it raised its outlook.
AppFolio, Inc. (NASDAQ:APPF), a provider of cloud software for the real-estate property-management industry, delivered strong revenue growth, crossed $1 billion in trailing revenue and expanded its margins andCash Flowin the second quarter, beating expectations and raising its guidance.
Arlo Technologies, Inc. (NYSE:ARLO), a maker of smart-home security cameras and services, delivered record revenue with surging paid subscribers and sharply higher profitability in the second quarter, beat expectations, and raised its outlook. In its latest close, the stock fell 4.41%.
Alvotech (NASDAQ:ALVO), a developer and manufacturer of biosimilar medicines, reported a sharp decline in first-half revenue in 2026 as a manufacturing-improvement program temporarily disrupted output, even as it reaffirmed its full-year guidance and advanced its regulatory pipeline.
AdvanSix Inc. (NYSE:ASIX), a diversified chemistry company that makes nylon, chemical intermediates and fertilizers, delivered sequential improvement and strong nylon sales in the second quarter, though margin pressure led to an earnings miss.